Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2

Página do item simplificado
dc.contributor.authorSchluckebier, Luciene
dc.contributor.authorGaray, Osvaldo U
dc.contributor.authorZukin, Mauro
dc.contributor.authorFerreira, Carlos G
dc.date.accessioned2022-08-10T14:36:07Z
dc.date.available2022-08-10T14:36:07Z
dc.date.issued2015
dc.description.abstractObjective: Pemetrexed plus carboplatin offers survival advantage in first line treatment of advanced lung cancer patients with performance status of 2. We estimated the cost-effectiveness of this combined regimen compared to pemetrexed alone in a Brazilian population. Methods: A cost-effectiveness analysis was conducted based on a randomized phase III trial in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status of 2 (PS2), comparing doublet regimen pemetrexed plus carboplatin with pemetrexed alone. The perspective adopted was the public health care sector over a three-year period. Direct medical costs and survival time were calculated from patient-level data and utility values were extracted from the literature. Sensitivity analyses were performed to evaluate uncertainties in the results. Results and conclusion: The combined regimen pemetrexed plus carboplatin yielded a gain of 0.16 life year (LY) and 0.12 quality-adjusted life year (QALY) compared to pemetrexed alone. The total cost was 17,674.31 USD for the combined regimen and 15,722.39 USD for pemetrexed alone. The incremental cost-effectiveness ratio (ICER) was $12,016.09 per LY gained and $15,732.05 per QALY gained. The factors with the greatest impact on the ICER are pemetrexed price and the time to progression utility value. The cost-effectiveness acceptability curve showed an upper 90% probability of pemetrexed plus carboplatin being cost-effective with a threshold between two and three GDP per capita. Our study suggests superiority of the combined pemetrexed plus carboplatin regimen in terms of efficacy as well as cost-effectiveness in advanced NSCLC patients with a poor performance status of 2.en
dc.identifier.citationSchluckebier L, Garay OU, Zukin M, Ferreira CG. Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2. Lung Cancer. 2015; 89:274-279. Doi: 10.1016/j.lungcan.2015.06.015.
dc.identifier.otherDOI: 10.1016/j.lungcan.2015.06.015.
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/80
dc.language.isoen
dc.publisherLung Cancer
dc.subjectLung Canceren
dc.subjectPemetrexeden
dc.subjectCost effectivenessen
dc.subjectNon-small cell lung canceren
dc.subjectPS2 patientsen
dc.subject.meshTreatment Outcomeen
dc.subject.meshQuality-Adjusted Life Yearsen
dc.subject.meshPemetrexed / therapeutic useen
dc.subject.meshPemetrexed / administration & dosageen
dc.subject.meshNeoplasm Stagingen
dc.subject.meshLung Neoplasms / pathologyen
dc.subject.meshLung Neoplasms / mortalityen
dc.subject.meshLung Neoplasms / drug therapyen
dc.subject.meshHumansen
dc.subject.meshCost-Benefit Analysisen
dc.subject.meshCarcinoma, Non-Small-Cell Lung / pathologyen
dc.subject.meshCarcinoma, Non-Small-Cell Lung / mortalityen
dc.subject.meshCarcinoma, Non-Small-Cell Lung / drug therapyen
dc.subject.meshCarboplatin / administration & dosageen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols / therapeutic useen
dc.titleCarboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Schluckebier L et al_2015.pdf
Tamanho:
737.4 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Bibliográfica
Produção Docente